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Background: Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene and afflicts
skeletal and cardiac muscles. Previous studies showed that DMD is associated with constitutive activation of NF-κB,
and in dystrophin-deficient mdx and utrophin/dystrophin (utrn-/-;mdx) double knock out (dko) mouse models,
inhibition of NF-κB with the Nemo Binding Domain (NBD) peptide led to significant improvements in both
diaphragm and cardiac muscle function.
Methods: A trial in golden retriever muscular dystrophy (GRMD) canine model of DMD was initiated with four
primary outcomes: skeletal muscle function, MRI of pelvic limb muscles, histopathologic features of skeletal muscles,
and safety. GRMD and wild type dogs at 2 months of age were treated for 4 months with NBD by intravenous
infusions. Results were compared with those collected from untreated GRMD and wild type dogs through a
separate, natural history study.
Results: Results showed that intravenous delivery of NBD in GRMD dogs led to a recovery of pelvic limb muscle
force and improvement of histopathologic lesions. In addition, NBD-treated GRMD dogs had normalized postural
changes and a trend towards lower tissue injury on magnetic resonance imaging. Despite this phenotypic improvement,
NBD administration over time led to infusion reactions and an immune response in both treated GRMD and wild
type dogs.
Conclusions: This GRMD trial was beneficial both in providing evidence that NBD is efficacious in a large animal DMD
model and in identifying potential safety concerns that will be informative moving forward with human trials.Background
Duchenne muscular dystrophy (DMD) is an X-linked re-
cessive disease, in which mutations in the gene coding
for the protein dystrophin lead to progressive degener-
ation of skeletal and cardiac muscles [1-3]. Glucocorti-
coids, such as prednisone, are the current standard of
care for DMD [4,5], but in spite of clinical benefits,
treatment must often be discontinued due to side effects
[6]. This has prompted use of many different glucocorticoid
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with fewer complications.
Treatments targeting NF-κB signaling are of particular
interest because glucocorticoids exert their effects, in
part, by blocking this pathway [7]. Studies have also
shown that NF-κB signaling is activated in DMD pa-
tients and exacerbates muscle lesions and dysfunction in
DMD mouse models [8,9]. NF-κB signaling occurs in re-
sponse to factors such as inflammatory cytokines [10].
These stimuli activate the inhibitor of kappa B kinase
(IKK) complex, which consists of two catalytic subunits
(IKKα and IKKβ) and a regulatory subunit (IKKγ/NEMO)
[11]. In resting cells, the inhibitor protein, IκB, binds and
maintains NF-κB in an inactive complex in the cytoplasm.
Upon activation, IKK phosphorylates IκB, leading to its
ubiquitination and subsequent degradation by the 26Sral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the nucleus and cooperate with basal transcription factors
to enhance transcription of its target genes.
The Nemo Binding Domain (NBD) peptide is a spe-
cific inhibitor of NF-κB that functions by binding to se-
quences within IKKα and IKKβ that permit interaction
with NEMO [12]. By effectively inhibiting assembly of
the IKK complex, NBD prevents activation of NF-κB.
Inhibiting NF-κB signaling with NBD reproducibly alle-
viates dystrophic histopathologic lesions and improves
muscle function in DMD mouse models. Specifically,
NBD-treated dystrophin-deficient mdx mice have re-
duced inflammation and injury, as well as enhanced re-
generation and function in skeletal muscles [9,13]. In
addition, NBD has been shown to prevent cardiac dys-
function in utrophin/dystrophin (utrn-/-;mdx) double
knock out (dko) mice [14]. Besides NBD, other strategies
to reduce NF-κB signaling in dystrophic or injured mice,
including the use of muscle derived stem cells deficient
in one copy of the p65/RelA NF-κB subunit [15], or with
gene therapy using viral interference of IKK activation
[16], have provided additional evidence that NF-κB inhib-
ition is advantageous for treating/repairing injured mus-
cles. Altogether, these studies have been encouraging,
indicating that NF-κB inhibition may be a viable avenue
for treating DMD.
Golden retrievers with muscular dystrophy (GRMD)
have a spontaneous mutation in the dystrophin gene and
develop phenotypic features typical of DMD [17-19].
Unlike the mdx mouse, which exhibits a mild and stable
phenotype when compared to the progressive disease in
DMD boys, affected GRMD dogs undergo progressive
fatal disease. This phenotypic similarity suggests that
studies in dystrophic dogs may effectively predict relevant
disease mechanisms and therapeutic efficacy. Indeed, the
GRMD model has been used increasingly in preclinical tri-
als of various therapeutic modalities, including genetic,
cellular, and pharmacologic approaches [20].
In the current study, we administered NBD intraven-
ously to GRMD dogs, employing a treatment protocol
and biomarkers used previously to establish both benefits
and potential deleterious effects of prednisone [21]. Con-
sistent with observations in mice, we found that NBD
treatment improved function and ameliorated muscle his-
topathologic lesions in GRMD dogs, supporting the use of
NBD as a therapeutic for DMD.
Methods
Intravenous dosing in mice
Mdx mice (C57BL/10ScSn-DMDmdx/J) were purchased from
The Jackson Laboratory and housed in the animal facility
(University Laboratory Animal Resources, ULAR) at The
Ohio State University under conventional conditions with
constant temperature and humidity, and fed with standarddiet. Treatment of mice was performed between 5 and
7 weeks of age as earlier described [13], and in accordance
with the guidelines of the Institutional Animal Care and Use
Committee at The Ohio State University. Efficacy of NBD
was assessed comparing four groups (n = 5 each) of mdx
mice treated either with vehicle or 3, 2, or 1 × per week with
NBD by intraperitoneal (IP) delivery. Two separate groups
(n = 10) were dosed subcutaneously (SQ) with vehicle or
NBD, and finally two groups (n = 5) were treated with vehicle
or NBD by intravenous (IV) delivery. Vascular access ports
(VAP) were placed subcutaneously over the dorsal torso and
a catheter was surgically inserted into the jugular vein. The
catheter was kept clear by a pre- and post-wash with heparin.
Canine experimental design
All dogs were produced in a colony at the University of
North Carolina at Chapel Hill (UNC-CH) and were used
and cared for according to principles outlined in the Na-
tional Research Council Guide for the Care and Use of
Laboratory Animals. The UNC-CH Institutional Animal
Care and Use Committee approved procedures.
The GRMD disease phenotype was initially determined
based on elevation of serum creatine kinase and confirmed by
PCR. Two cohorts of GRMD dogs were treated with a 4-
month course of NBD (10 mg/kg, IV) (American Peptides;
Sunnyvale, CA, USA) [13], beginning at approximately
2 months of age. The first cohort included four GRMD (Wa-
sabi, Pepper, Hiver, and Automne) and two wild type (Cumin
and Fennel) dogs, while the second cohort included two
GRMD (Peach and Kiwi) and one wild type (Mango) dog. Re-
sults were compared with those collected from 10 untreated
GRMD dogs (Cilantro, Lyle, Napoleon, Summer, Jane,
Cosmo, Dorothy, Toto, Hickory, and Zeke) and eight age-
matched wild type littermates (Oregano, Parsley, Kip, Pedro,
Pinkman, Saul, Heisenberg, and Tuco) through a parallel, but
separate, natural history study in which functional, magnetic
resonance imaging (MRI), and pathologic data were collected.
NBD preparation and administration
NBD peptide (TALDWSWLQTE) fused to an Antennape-
dia protein transduction domain [9] was generated using an
ABI 430A solid-phase peptide synthesizer (Applied Biosys-
tems, Foster City, CA, USA) as previously described [13].
NBD solutions (10 mg/mL) for the canine studies were pre-
pared weekly. Needed volumes were calculated based on
the current dog body weights, plus estimated weekly gain
averages. Compound was weighed on a laboratory balance
to the nearest 0.1 g and reconstituted in sterile water. Solu-
tion was then sterile-filtered through 0.22 μm filters into a
sterile fluid administration bag and refrigerated at 4°C until
use. Daily administration volumes (total volume for all dogs
perfused for the day) were drawn up into a sterile 20 or
60 mL syringe, fitted with an intravenous tubing extension
set, and loaded into a syringe pump (Medfusion™ 3500
Kornegay et al. Skeletal Muscle 2014, 4:18 Page 3 of 17
http://www.skeletalmusclejournal.com/content/4/1/18Syringe Pump; SmithsMedical, St Paul, MN, USA). Prior to
perfusion, dogs were premedicated with butorphanol
(0.4 mg/kg, IM); once infusion reactions were seen, diphen-
hydramine (2.0 mg/kg, SQ) was also given. Heart and re-
spiratory rate, mucous membrane color, capillary refill time,
and body temperature were monitored throughout the per-
fusion. Approximately 10 to 20 min after premedication,
intravenous catheters (22 to 24 gauge) were placed sterilely
into either the cephalic or saphenous vein. The syringe
pump was initially programed to administer the calculated
volume over 10 min, but this was extended to 30 min when
reactions were seen. Blood pressure was recorded prior to
start of perfusion, at 5-min intervals throughout perfusion,
and post-perfusion (Cardell® 9405MultiparameterMonitor,
Midmark Corporation, Versailles, OH, USA). Dogs were
monitored for adverse reactions throughout the perfusion
and for up to 30min after completion.
Pharmacokinetic (PK) measurements
PK studies were performed at Sinclair Research Center
(Auxvasse, MO, USA). Whole blood was collected from
normal mice (0.5 to 1.0 mL; n = 3/time point) and bea-
gle dogs (3.0 mL; n = 3/group) at 0, 0.08, 0.25, 0.5, 1, 2,
4, 8, and 24 h following IV dosing with NBD at 2 and
10 mg/Kg and transferred into pre-labeled tubes con-
taining EDTA as an anticoagulant. Plasma was prepared
and shipped overnight to Frontage Labs (Malvern, PA,
USA) for PK evaluations. PK calculations were performed
using WinNonlin Professional software from plasma con-
centration, and parameters were determined directly from
the plasma concentration.
Tibiotarsal joint (TTJ) force measurements
For all tests, dogs were anesthetized (premeds: acepro-
mazine maleate (0.02 mg/kg), butorphanol (0.4 mg/kg),
and atropine sulfate (0.04 mg/kg); masked/intubated;
and maintained with sevoflurane). To assess force and
eccentric contraction decrement (below), dogs were po-
sitioned in dorsal recumbence in a custom-made stereo-
tactic frame that aligns the tibia parallel to the table at a
90° angle to the femur. The angle at which maximal joint
torque is generated during isometric contractions has
been termed the optimal joint angle [22], which is analo-
gous to the optimal fiber length (Lo) for individual
muscle force measurements. Our choice of 90° as the
optimal joint angle was based on studies in which torque
was measured over a range of angles [23]. The length-
tension relationship was not shifted for normal versus
GRMD dogs. TTJ flexion and extension torque (N-m) was
measured by a rapid-response servomotor/force trans-
ducer (model 310B LR, Aurora Scientific, Inc., Aurora,
ON, Canada) controlled by a PC using custom LabView
software [24,25]. Either the common peroneal (TTJ
flexion) or tibial (TTJ extension) nerve was stimulatedusing paired stimulating and reference 27-gauge monopo-
lar electrodes placed just distal to the fibular head (com-
mon peroneal nerve) or within the gastrocnemius muscles
(tibial nerve), respectively. As a result, the paw of the distal
pelvic limb pulled (flexion) or pushed against (extension) a
pedal affixed to a transducer, providing a measure of iso-
metric torque. Supramaximal 150 V, 100 μs pulses were
applied (Model S48 Solid State Square Wave Stimulator;
Grass Instruments, Quincy, MA, USA) in a tetanic run of
250 pulses (50/s). The site of contact for the paw with the
lever (moment arm) was estimated to be 75% of the dis-
tance between the point of the hock and the distal digit.
Torque (Newton-meters) was divided by the moment arm
(meters) to convert to force (Newtons).Eccentric contraction decrement (ECD)
Eccentric contractions were induced by stimulating the
peroneal nerve using square wave pulses of 100 μs dur-
ation in a tetanic run for 1 s at a frequency of 50 Hz
while simultaneously extending the TTJ with a servo-
motor (Aurora Scientific, Aurora, ON, Canada) [24-26].
The contraction was held isometric at the optimal joint
angle [22], expressed as Lo here (see discussion above),
for the first 900 ms. For the final 100 ms, the muscles of
the cranial tibial compartment were stretched by the
servomotor at 0.7 Lo/s, such that the muscles were dis-
placed to 107% of Lo. Thus, the muscles of the cranial
tibial compartment were repeatedly stretched to induce
mechanical damage. Three sets of 10 stretches for a total
of 30, each set separated by 4 min, were performed.
Contraction-induced injury was quantified by the force
(torque) deficit (Fd) using the following equation: Fd =
(Maximal isometric tetanic force (Po) before stretch - Po
after stretch/Po before stretch) × 100.Joint angles
We previously reported that 6-month-old GRMD dogs
have abnormally acute (contracted) TTJ angles while po-
sitioned in dorsal recumbence for force measurements
[27,28]. Other investigators have subsequently described
methods to measure joint angles at maximal flexion and
extension, with associated range of motion, in wild type
dogs [29,30]. The method of Jaegger et al. [29] is now
utilized to measure pelvic limb tibiotarsal (hock, ankle),
stifle (knee), and coxofemoral (hip) joint angles for on-
going natural history and preclinical trials in our labora-
tory. In each case, dogs were anesthetized (above) and
positioned in lateral recumbence. Angles at rest, max-
imal flexion, and maximal extension were measured. To
objectively characterize the cranioventral shift of the pel-
vis typically seen in GRMD dogs, we also measured the
pelvic angle formed by two lines extending cranially from
the tuber ischium, one drawn parallel to the lumbar spine
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coxae.
Magnetic resonance imaging
Studies were done on a Siemens 3 T Allegra Head-Only
MRI scanner with a circular polarization (CP) head coil
or Siemens 3 T Tim Trio Whole-Body MRI scanner
with a 32-channel body coil at the UNC-CH Biomedical
Research Imaging Center (BRIC) [31,32]. Dogs were
anesthetized (above), placed on an MRI gantry in the
sternal (prone) position with the pelvic limbs extended,
and positioned in the coil centered at the midpoint of
the femur. The proximal pelvic limbs from the coxofe-
moral joint to the stifle were imaged bilaterally. Scans
were completed using a published protocol [31,32]. T2-
weighted image sequences without (T2w) and with fat
saturation (T2fs) were acquired using a variable-flip-
angle turbo spin echo (TSE) sequence. The time be-
tween the excitation pulse and the center of k-space was
400 ms. Importantly, the contrast was not determined
only by the TE (400 ms), but also by the flip angle evolu-
tion scheme. Although a traditional TSE sequence would
have very little signal at 400 ms, the variable flip angle
sequence is similar in principle to hyper-echo. The
hyper-echo reduces the specific absorption rate (SAR),
while the variable flip angle sequence allows long TE
times [33,34]. A multi-spin-echo T2 (MSE-T2), using a
10-echo Carr-Purcell-Meiboom-Gill sequence, was ac-
quired to calculate the T2 value map. Analysis of the
images was completed in three modules: muscle seg-
mentation, pre-processing, and biomarker analysis. As a
prerequisite, we first segmented the major proximal pel-
vic limb muscles in the MRI images. All proximal pelvic
limb muscles were segmented but only five slices at the
midfemur were analyzed and averaged.
For the sake of this study, the biomarker analysis was
limited to muscle volumes, T2 mapping values, and sev-
eral texture analysis features, including a first-order in-
tensity histogram texture feature (entropy) and two high
order run length matrix features (short run emphasis
(SRE) and run length non-uniformity (RLN)). These tex-
ture analysis features were assessed as potential markers
of patchy lesions such as necrosis [31,32,35,36]. Based on
the mathematical model, we refer to short run emphasis
as the Small Lesion Index (SLI) and non-uniformity as the
Heterogeneity Index (HI). Both SLI and HI use the run-
length matrix method. Compared to histogram-based bio-
markers that use intensity data only, the run-length matrix
method also takes into account the spatial distribution
and intensity of the voxels. A gray-level ‘run’ is defined as
a set of consecutive voxels of similar intensity level in a
given direction within a predefined similarity range. This
is run in a three-dimensional matrix and is intended to
detect lumps of hyper-intensity in MRI. To determineoverall muscle scores for T2 and the texture features in
each group, the proportional muscle volume was consid-
ered, so as to calculate a weighted average.
Cranial sartorius (CS) circumference
We have previously shown that the CS muscle under-
goes dramatic hypertrophy in GRMD dogs and that this
hypertrophy tracks with postural abnormalities [37]. Ac-
cordingly, we use CS circumference measured at surgery
during routine biopsy as a surrogate for muscle hyper-
trophy and associated postural changes in GRMD [24].
Dogs were anesthetized (above), and an incision was
made over the cranial aspect of the thigh. In advance of
biopsy, the CS muscle was isolated. Nylon suture was
placed around the muscle at approximately midsection
and tightened so as to snugly encircle the muscle belly.
The two ends of the suture were secured with a pair of
hemostats and then cut on the muscle side of the
hemostat. The length in mm was divided by body mass
in kg (mm/kg). An average of two measurements was
recorded.
Histopathologic assessments
For mice muscles, histopathological assessment was per-
formed as earlier described [13]. For canine samples, CS,
lateral gastrocnemius, vastus lateralis, and diaphragm
muscles were assessed at the end of the 4-month treat-
ment period when dogs were necropsied. Muscle sam-
ples were snap frozen in isopentane cooled in liquid
nitrogen, and stored at -80°C. A total of 16 dogs (3 wild
type, 2 wild type + NBD, 5 untreated GRMD, and 6
GRMD +NBD) were assessed. Serial frozen sections
(n = 10 per dog) from each muscle were processed. For
each stain, quantitation was performed on three 10 μm
sections of each muscle. To determine the degree of in-
flammation, cells that stained with a canine specific
macrophage PM2K antibody were quantitated. Muscle
damage was assessed by scoring for IgG-positive myofi-
bers using immunofluorescence, and necrotic foci by
hematoxylin and eosin (H&E) staining. Centrally located
nuclei (CLN) were quantified on H&E sections to deter-
mine the degree of regeneration. Staining was quantitated
on an Olympus BX51 microscope with Microsuite Five
software (Olympus Soft Imaging Solutions GmbH, Center
Valley, PA, USA). A composite score for all four muscles,
reflecting muscle injury, inflammation, and regeneration,
was determined.
Necropsies were completed on all six of the NBD-
treated GRMD dogs and two of the wild type dogs. Sec-
tions of kidney, liver, spleen, lung, heart (right and left
ventricle), popliteal lymph node, adrenal gland, thyroid,
duodenum, large intestine, pancreas, stomach, and cere-
brum were collected and fixed in 10% buffered formalin.
Tissues were sent to Histo-Scientific Research Laboratories
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where they were processed, embedded in paraffin, sec-
tioned, and stained with H&E. An American College of
Veterinary Pathology-certified pathologist evaluated slides.
Statistics
For the functional and MRI studies, we focused on com-
parisons between two types of wild type dogs (3 wild
type dogs treated with NBD versus 8 wild type natural
history dogs) and between two types of GRMD dogs (6
GRMD dogs treated with NBD versus 10 GRMD natural
history dogs). For all dogs, MRI scans were obtained at
around 6 months of age (171.0 ± 10.9 days). To compare
the MRI features between two groups, we carried out a
two-sample t-test for each muscle. This test is known as
Welch’s t-test since the two data groups have unequal
sample sizes and the group variances are assumed to be
unequal [38]. We also compared the functional data on
both the natural history (wild type and GRMD) and
GRMD dogs treated with NBD. For each dog, we uti-
lized the t-test for comparing two groups at each age.
For all functional and MRI tests, we applied the FDR
method to correct the P values [39]. Significance was set
at P <0.05; trends were reported when P <0.2. Histopatho-
logic data were analyzed using an unpaired Student t-test.
A two-tailed P value of <0.05 was considered significant.
Results
Establishing a delivery and dosing schedule for NBD in
the mdx mouse
Previous results in mdx and dko mice showed that intra-
peritoneal (IP) dosing of NBD, 3× per week, was effica-
cious in improving function in skeletal and/or cardiac
muscle and lessening histopathologic lesions of skeletal
muscles [13,14]. In addition, we showed that this re-
sponse was dose dependent, as efficacy was lost when
concentrations of NBD were reduced from 10 to 2 mg/
kg [13]. To further optimize NBD delivery, we tested
whether benefits could be maintained by dosing mdx
mice at 10 mg/kg at 2× or 1× per week. In comparison
to our standard 3× per week schedule, histopathologic
improvement was less pronounced with reduced treat-
ment frequencies (Figure 1A). Next, we tested different
administration routes since IP delivery is not feasible for
DMD patients. While our previous findings showed that
IP delivery of NBD was effective in significantly reducing
muscle inflammation and necrosis [9,13,40], no such
improvements were observed following subcutaneous
dosing (Figure 1B). In contrast, delivering NBD by intra-
venous (IV) dosing for 4 weeks using a VAP, which
allowed repeated dosing through a catheter line, resulted
in significant histopathologic improvement in mdx skel-
etal muscles (Figure 1C). This suggested that IV delivery
might be a suitable route for dosing NBD in largerspecies. This point was further supported by PK mea-
surements, which showed a dose dependent increase of
NBD in the blood of normal mice following single IV
injections of the peptide at 2 and 10 mg/kg (Additional
file 1: Figure S1A).
Establishing a treatment paradigm for GRMD dogs
Having established a treatment regimen that provides ef-
ficacy of NBD in mice, we next asked whether such ther-
apy could be applied to a larger animal model of DMD.
PK studies after IV delivery of NBD to normal beagle
dogs showed there was a dose dependent increase of
NBD following injections of 2 and 10 mg/kg of peptide
(Additional file 1: Figure S1B). This PK profile was com-
parable to that of mice, suggesting that the murine dos-
ing regimen would extrapolate to dogs. In addition,
normal hematology (white blood cell, red blood cell,
platelet counts) and serum chemistry (ALT, AST, GGT,
bilirubin, creatinine, potassium, creatine kinase) profiles
were noted following a single IV injection of NBD in
normal dogs (data not shown). Based on our collective
data, a preclinical trial in GRMD dogs was initiated with
four primary outcomes: skeletal muscle function, MRI of
pelvic limb muscles, histopathologic features of skeletal
muscles, and safety. Juvenile GRMD (n = 6) and wild
type (n = 3) dogs at 2 months of age were treated for
4 months by IV infusions, 3× weekly, at 10 mg/Kg. Re-
sults were compared with those collected from untreated
GRMD and wild type dogs through a separate, natural
history study.
NBD treatment enhances GRMD muscle function and
reduces postural abnormalities
TTJ force
We have previously assessed force generated by TTJ
flexion and extension in both natural history and pre-
clinical studies [20,23]. Data from a recently completed
natural history study were compared with results from
NBD-treated GRMD dogs at 6 months of age (Table 1).
Force values, corrected for body weight, were used as
the primary outcome parameter to be consistent with
the prior studies. Presumably owing to changes in in-
strumentation and methodology [24,25], these natural
history data differ somewhat from our previously pub-
lished results, making direct comparison difficult. Im-
portantly, data from the control natural history and
NBD-treated dogs reported here were collected using
the same instrumentation and over a similar time frame.
GRMD dogs treated with NBD for 4 months exhibited
a significant 73% increase in extension force when com-
pared to untreated GRMD dogs (2.70 ± 0.65 vs. 1.56 ±
0.92 N/kg; P = 0.038) (Figure 2A, Table 1). In a previous
GRMD prednisone trial, treated dogs also had increased
extension force [21]. This functional benefit obtained by
Figure 1 Establishing a delivery and dosing schedule for NBD in mdx mice. (A) Mdx mice were treated by IP delivery for a period of
4 weeks with NBD (10 mg/kg) for either 3 days (d), 2 days, or 1 day per week. Quadriceps (Quad) muscles were selected as a representative hind
limb muscle from NBD treated mdx mice (n = 5 per group). (B) Mdx mice were treated with vehicle or NBD (10 mg/kg), 3× weekly, by SQ
delivery, for a period of 4 weeks. Quad muscles were analyzed from NBD and vehicle treated mdx mice (n = 10 per group). (C) Mdx mice were
treated with vehicle or NBD (10 mg/kg) 3× weekly, by IV delivery for a period of 4 weeks. Quad muscles were analyzed from NBD and vehicle
treated mice (n = 5 per group). For all panels, muscle sections (3 per muscle) were either immunostained with the macrophage marker, F4/80, to
measure inflammation, or incubated with a fluorescent conjugated immunoglobin (IgG) to assess necrosis, or stained with the embryonic form of
myosin heavy chain (eMyHC) to detect regenerative myofibers. Data are expressed as percentage of marker expression per total area. Asterisks
indicate P = 0.05 (*), P <0.01 (**), P <0.001 (***).
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Table 1 Phenotypic measures in NBD-treated and untreated GRMD and normal dogs
Test
Normal (Untreated) (n = 8) Normal (NBD-treated) (n = 3) GRMD (Untreated) (n = 10) GRMD (NBD-treated) (n = 6)
Age (months) Age (months) Age (months) Age (months)
3 6 2 6 3 6 2 6
Body Mass (kg) 8.46 ± 0.632* 17.80 ± 0.441***,2*** 4.99 ± 1.83 21.10 ± 3.151* 7.36 ± 1.29 13.40 ± 2.201*** 3.60 ± 0.27 12.70 ± 2.811**
Absolute Tetanic Flexion Force (N) 9.51 ± 1.072*** 23.19 ± 2.201***,2*** 4.52 ± 1.82 25.75 ± 2.181** 3.85 ± 1.13 7.85 ± 1.981*** 2.05 ± 0.58 6.79 ± 1.131***
Body-mass Corrected Tetanic Flexion Force (N/kg) 1.12 ± 0.102*** 1.30 ± 0.131*,2*** 0.90 ± 0.042** 1.24 ± 0.19 0.53 ± 0.14 0.62 ± 0.18 0.57 ± 0.15 0.55 ± 0.13
Absolute Tetanic Flexion Torque (Nm) 1.08 ± 0.142*** 3.22 ± 0.351***,2*** 0.42 ± 0.24 3.65 ± 0.431** 0.43 ± 0.14 1.03 ± 0.231*** 0.17 ± 0.06 0.89 ± 0.181***
Body-mass Corrected Tetanic Flexion Torque (Nm/kg) 0.13 ± 0.012*** 0.18 ± 0.021***,2*** 0.08 ± 0.02 0.17 ± 0.02 0.06 ± 0.02 0.08 ± 0.02 0.05 ± 0.01 0.07 ± 0.021*
Absolute Tetanic Extension Force (N) 22.56 ± 2.762*** 46.43 ± 8.441***,2*** 13.46 ± 3.26 42.17 ± 7.461* 12.73 ± 2.12 18.47 ± 10.11 7.50 ± 2.09 34.30 ± 9.651**,2*
Body-mass Corrected Tetanic Extension Force (N/kg) 2.68 ± 0.382** 2.61 ± 0.492** 2.88 ± 1.10 2.00 ± 0.22 1.80 ± 0.52 1.56 ± 0.92 2.11 ± 0.70 2.70 ± 0.652*
Absolute Tetanic Extension Torque (Nm) 2.55 ± 0.372*** 6.44 ± 1.241***,2*** 1.20 ± 0.41 6.02 ± 1.381* 1.42 ± 0.23 2.46 ± 1.28 0.62 ± 0.16 4.55 ± 1.491**,2*
Body-mass Corrected Tetanic Extension Torque (Nm/kg) 0.30 ± 0.042*** 0.36 ± 0.072*** 0.25 ± 0.08 0.28 ± 0.04 0.20 ± 0.05 0.18 ± 0.10 0.21 ± 0.07 0.36 ± 0.081*,2**
ECD (%; 1-10) 13.68 ± 3.97 8.29 ± 2.881*,2** 13.36 ± 2.65 14.47 ± 7.31 13.97 ± 10.52 28.96 ± 18.07 16.12 ± 5.88 32.04 ± 13.46
ECD (%; 1-30) 26.80 ± 5.922* 17.86 ± 5.201*,2*** 33.44 ± 10.3 23.25 ± 17.4 36.51 ± 11.49 54.30 ± 14.731* 38.67 ± 10.34 54.48 ± 13.64
TTJ Angle (o) 167.9 ± 3.942*** 160.9 ± 3.401**,2* 161.7 ± 7.64 158.3 ± 2.08 159.40 ± 3.72 151.30 ± 10.19 157.00 ± 9.80 160.17 ± 8.84
Hip (Resting) 99.50 ± 5.10 104.4 ± 5.76 99.33 ± 1.15 103.0 ± 11.4 103.4 ± 8.96^ 109.6 ± 8.02 103.7 ± 2.94 100.2 ± 6.012*
Maximum Hip Flexion (o) 55.50 ± 8.86 59.00 ± 12.60 48.67 ± 7.77 53.33 ± 10.12 54.40 ± 7.50^ 68.60 ± 16.15 44.67 ± 5.47 46.33 ± 3.502**
Pelvic Angle (o) 43.75 ± 5.12 36.14 ± 5.982** 38.33 ± 1.53 40.33 ± 5.03 40.00# 48.30 ± 5.54 41.00 ± 6.81 36.83 ± 5.122**
CS Circumference (mm/kg) NA 2.09 ± 0.402*** NA 2.30 ± 0.49 NA 4.03 ± 1.04 NA 3.67 ± 0.65
Functional studies, chiefly TTJ tetanic force and pelvic limb joint angles, were assessed to demonstrate therapeutic benefit of NBD in GRMD dogs and potential effects in wild type dogs. N = Newtons; Nm = Newton
meters; ECD = Eccentric contraction deficit; CS = Cranial Sartorius; TTJ = tibiotarsal joint.
^Data for only five GRMD dogs available at 3 mos.
#Data for only one GRMD dog available at 3 mos.
1Significantly different from 2/3 to 6 mos, same genotype; *p < 0.05, **p < 0.01; ***p < 0.001.
2Significantly different from GRMD natural history; *p < 0.05, **p < 0.01; ***p < 0.001.
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Figure 2 NBD treatment improves extension force in GRMD
dogs. Wild type and GRMD dogs were administered NBD IV at
10 mg/kg dose, 3× weekly for 4 months. Tibiotarsal joint (TTJ)
tetanic extension (A) and flexion (B) force were measured in NBD-
treated wild type and GRMD dogs and compared to untreated wild
type GRMD control data from a separate natural history study.
Extension force was significantly increased (P <0.05 [*]) in NBD-
treated GRMD dogs compared to untreated dogs. Flexion force was
lower in GRMD dogs treated with NBD but the difference was not
significant. White bars represent wild type dogs, while black bars
represent GRMD dogs, either untreated or treated with NBD.
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in the mdx murine model of DMD [13]. Interestingly,
with both prednisone and NBD treatment, body weight
corrected flexion force was reduced in treated versuscontrol dogs, although differences did not reach signifi-
cance. Neither extension nor flexion force differed sig-
nificantly between wild type control and NBD-treated
dogs (Figure 2A and B, Table 1).
Eccentric contraction decrement (ECD)
GRMD dogs, like mdx mice, exhibit a force decrement
with eccentric (lengthening) contractions [26]. We mea-
sured the degree of ECD of TTJ flexors while a servo-
motor simultaneously extended the joint. As with our
prior study, ECD in GRMD dogs was higher than that of
wild type dogs at 6 months (Table 1). Values in NBD-
treated dogs after 10 and 30 contractions (32.0% ±13.5;
54.5% ±13.6) did not differ from those from the natural
history GRMD dogs (29.0% ±18.1; 54.3% ±14.7). Thus,
our findings indicate that NBD treatment does not
stabilize the muscle cell membrane, in contrast to what
would be expected with dystrophin transgenes and sur-
rogates [41,42]. These data are consistent with our earl-
ier conclusion in mdx mice that protection of dystrophic
muscles through NF-κB inhibition does not result from
increased membrane stability [9]. The ECD values for
control and NBD-treated wild type dogs did not differ
(Table 1).
Joint angles
Joint angles were measured to determine the severity of
contractures and overall postural instability. Proximal
pelvic limb joint and postural changes in GRMD dogs
appear to contribute to their characteristic plantigrade
tarsal stance, just as relative sparing of proximal flexor
muscles plays a role in distal limb flexor contractures in
DMD [43,44]. Indeed CS muscle circumference cor-
rected for body weight correlates negatively with TTJ
angle in GRMD dogs [24]. This suggests that the hyper-
trophied CS muscle might play a role analogous to ilioti-
bial band tightness in DMD [45].
We measured angles at rest and with maximum
flexion and extension at the three pelvic limb joints
using a standard technique [29]. Resting (Figure 3A,
Table 1) and flexion (Figure 3B, Table 1) hip angles were
smaller (less restricted) in the NBD treated versus con-
trol GRMD dogs. To further characterize postural
changes typical of GRMD [20], we measured the pelvic
angle formed by the spine and a line drawn between the
tuber ischium and the tuber coxae. The pelvic angle
values were significantly reduced in NBD treated versus
untreated GRMD dogs (Figure 3C, Table 1). Joint angles
for control and NBD treated wild type dogs did not
differ (Figure 3, Table 1). Taken together, joint angle
changes in treated GRMD dogs were consistent with less
pronounced postural deformity, which could reflect re-
duced muscle necrosis/inflammation and an associated
reduction in flexor muscle hypertrophy.
Figure 3 NBD treatment reduces postural changes in GRMD
dogs. Joint angles were measured to determine if NBD treatment
improved postural changes in GRMD dogs. Angles formed by the
hip at rest (A) and with maximal flexion (B) and the line of the
pelvis (C) were reduced (less restricted) in GRMD dogs treated with
NBD compared to untreated controls. P <0.05 (*), P <0.01 (**). White
bars represent wild type dogs, while black bars represent GRMD
dogs, either untreated or treated with NBD.
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features supporting a phenotype of reduced necrosis or
inflammation
The potential role of MRI as a biomarker in GRMD has
been reported in both natural history [31,32,46-48] and
preclinical [49] papers. Various parameters have been
assessed, with T2 signal intensity used most commonly
as a feature of either increased fluid or fat. T2 signal was
decreased in GRMD dogs treated systemically with mor-
pholinos to restore dystrophin expression compared to
age-matched untreated dogs in one study [49], support-
ing a role for MRI as a biomarker in preclinical studies.
We recently completed an MRI natural history study of
proximal pelvic limb muscles of GRMD and wild type
dogs over the first 9 to 12 months of age [32]. The most
striking differences were seen between 3 and 6 months, in-
dicating that biomarkers assessed over this period would
most likely reflect therapeutic benefit. Muscle volume and
the texture analysis biomarker, run length non-uniformity
(termed Heterogeneity Index [HI] here), differed most
markedly. The biceps femoris, semitendinosus, and CS
muscles demonstrated the greatest differential progression
in GRMD versus wild type dogs [32].
Based on these natural history data, we assessed MRI
at 6 months as an additional outcome measure for NBD
treatment of GRMD dogs, focusing on muscle volume,
T2 mapping values, and two texture analysis features, HI
and short run emphasis (termed small lesion index (SLI)
here). Texture analysis features were included because
they take into account the spatial distribution of lesions,
potentially highlighting the patchy nature of necrosis.
For T2 mapping, there was a strong trend for lower
values in all muscles considered as a whole in NBD-treated
GRMD dogs (47.3 ± 3.10) when compared to untreated
GRMD controls (52.3 ± 4.52) (P = 0.092) (Figure 4A;
Table 2). Interestingly, NBD treatment also lowered T2
values in wild type dogs (35.9 ± 0.47) compared to un-
treated wild type (40.8 ± 5.21) controls (P = 0.076). When
T2 mapping values for individual muscles were assessed,
the greatest effect was in the semitendinosus, biceps
femoris, and the vastus lateralis and intermedius heads of
the quadriceps femoris, all having P values <0.1.
Of the texture analysis features, SLI for all muscles
considered together trended towards being higher in the
untreated (0.75 ± 0.04) versus NBD-treated (0.70 ± 0.04)
Figure 4 MRI values differed between NBD-treated and
untreated GRMD and wild type dogs. Overall weighted average
muscle scores for T2 mapping values (A) and the two texture
analysis features, short run emphasis (Small Lesion Index; SLI) (B) and
run length non-uniformity (Heterogeneity Index; HI) (C) were lower
in wild type versus GRMD dogs. Each trended even lower with NBD
treatment. The median and upper and lower quartiles for each value
are identified. White bars represent wild type dogs, while gray bars
represent GRMD dogs, either untreated or treated with NBD.
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ing with more pronounced patchy lesions, such as ne-
crosis, that would disrupt the pixel run lengths of
homogeneous normal muscle. The pattern of individual
muscle involvement largely paralleled that of the T2
map, with the semitendinosus, biceps femoris, gracilis,
rectus femoris, and vastus lateralis all having P values <0.1.
The HI feature of all muscles taken together was also
higher in untreated GRMD dogs (103.5 ± 22.4) compared
to those treated with NBD (86.0 ± 18.3) (P = 0.229)
(Figure 4C, Table 2). On the other hand, CS texture fea-
tures did not distinguish treated and control GRMD dogs,
with T2 and SLI values being essentially identical and
those for HI showing only a modest insignificant lowering
in treated dogs. This reflects the differential disease effect
evident in the CS [32,37]. Values for untreated wild type
dogs (SLI, 0.66 ± 0.08; HI, 71.1 ± 27.9) were lower than
those with GRMD and even lower in the NBD-treated
group (SLI, 0.63 ± 0.04; HI, 47.1 ± 10.2) (SLI, P = 0.726;
HI, P = 0.205). Values for T2, SLI, and HI tracked
with one another, pointing towards shared underlying
lesions (Table 2). Taken together, the T2, SLI, and HI
results are compatible with an anti-inflammatory effect of
NBD and an associated reduction in fluid accumulation
and necrosis.
NBD treatment improves histopathological lesions of
GRMD muscles
For pathologic studies, we were particularly interested in
the CS muscle, as it undergoes early necrosis followed
by true hypertrophy and subsequent fibrosis in GRMD
[37]. The degree of hypertrophy correlates with TTJ force
measurements and joint angles, and generally tracks with
a more severe phenotype [24]. Accordingly, we included
CS circumference at 6 months of age as an endpoint
measure to determine the efficacy of NBD. Consistent
with MRI findings, untreated GRMD dogs had a larger CS
circumference (4.03 ± 1.04) compared to wild type con-
trols (2.09 ± 0.40) (P <0.001) (Table 1). CS size was re-
duced in NBD-treated (3.67 ± 0.65) vs. untreated GRMD
dogs, but this difference was not significant (P = 0.408).
The hypertrophic response in CS muscles was clearly ob-
servable on measurements of myofiber size in a subset of
untreated GRMD (n = 5, 1,500 fibers) versus wild type
Table 2 MRI T2 and texture analysis features in NBD-treated and untreated GRMD and wild type dogs
Muscle Normal (Untreated) (n = 8) Normal (NBD-treated) (n = 3) GRMD (Untreated) (n = 10) GRMD (NBD-treated) (n = 6)
T2 SLI HI T2 SLI HI T2 SLI HI T2 SLI HI
Cranial Sartorius 49.40 ± 9.01 0.79 ± 0.09 66.80 ± 18.58 47.72 ± 6.86 0.74 ± 0.04 59.82 ± 29.72 49.87 ± 6.44 0.79 ± 0.05 74.01 ± 27.15 49.40 ± 9.01 0.79 ± 0.05 59.82 ± 14.91
Caudal Sartorius 53.87 ± 9.88 0.72 ± 0.12 27.96 ± 15.47 54.02 ± 4.79 0.81 ± 0.04 35.21 ± 9.28 59.71 ± 7.02 0.83 ± 0.07 56.90 ± 30.08 53.87 ± 9.88 0.83 ± 0.05 35.21 ± 14.92
Vastus Lateralis 40.67 ± 5.84 0.62 ± 0.07 66.18 ± 28.71 36.60 ± 1.37 0.63 ± 0.12 52.92 ± 23.51 49.84 ± 5.35 0.75 ± 0.07 69.42 ± 18.85 40.67 ± 5.84^ 0.68 ± 0.04^ 52.92 ± 27.20
Vastus Intermedius 41.91 ± 5.91 0.66 ± 0.19 42.44 ± 21.75 36.03 ± 0.73^ 0.58 ± 0.06 59.10 ± 9.05 52.62 ± 6.33 0.75 ± 0.06 69.83 ± 39.19 41.91 ± 5.91^ 0.68 ± 0.09 59.10 ± 27.19
Vastus Medialis 42.74 ± 5.65 0.72 ± 0.11 63.20 ± 23.57 35.80 ± 0.94^ 0.64 ± 0.06 52.55 ± 9.41 53.60 ± 7.16 0.82 ± 0.06 41.13 ± 14.73 42.74 ± 5.65 0.77 ± 0.09 52.55 ± 22.29
Rectus Femoris 37.23 ± 4.72 0.70 ± 0.06 55.30 ± 29.46 33.30 ± 2.41 0.64 ± 0.03 55.42 ± 3.46 49.44 ± 5.71 0.78 ± 0.06 57.02 ± 23.66 37.23 ± 4.72 0.68 ± 0.07^ 55.42 ± 21.95
Biceps Femoris 40.20 ± 4.91 0.67 ± 0.06 91.36 ± 35.35^ 34.94 ± 0.40 0.62 ± 0.07 87.50 ± 11.65 50.13 ± 4.78 0.76 ± 0.06 137.3 ± 40.91 40.20 ± 4.91^ 0.68 ± 0.06^ 87.50 ± 48.42
Semimembranosus 39.42 ± 4.86 0.63 ± 0.08 49.75 ± 20.32 35.24 ± 1.17 0.63 ± 0.10 78.15 ± 20.38 52.28 ± 4.55 0.71 ± 0.07 121.4 ± 59.04 39.42 ± 4.86 0.68 ± 0.06 78.15 ± 33.31
Semitendinosus 40.41 ± 4.97 0.61 ± 0.19 44.65 ± 21.35 36.59 ± 2.18 0.61 ± 0.13 81.43 ± 38.69 56.09 ± 6.02 0.77 ± 0.07 128.1 ± 42.03 40.41 ± 4.97^ 0.67 ± 0.08^ 81.43 ± 35.00
Adductor 39.52 ± 4.76 0.67 ± 0.11 87.90 ± 42.89 34.69 ± 0.91^ 0.64 ± 0.00 116.18 ± 7.79 50.49 ± 5.19 0.72 ± 0.05 84.12 ± 33.68 39.52 ± 4.76 0.72 ± 0.02 116.2 ± 22.37
Gracilis 45.91 ± 3.50 0.63 ± 0.13 59.83 ± 38.30 38.27 ± 0.93** 0.62 ± 0.06 58.90 ± 24.51 58.56 ± 5.19 0.78 ± 0.05 104.2 ± 34.65 45.91 ± 3.50 0.70 ± 0.06^ 58.90 ± 30.66
All 40.81 ± 0.47 0.66 ± 0.08 71.06 ± 27.89 35.90 ± 0.47^ 0.63 ± 0.04 47.12 ± 10.24 52.28 ± 4.52 0.75 ± 0.04 103.47 ± 22.40 47.34 ± 3.10^ 0.70 ± 0.04^ 86.01 ± 18.28
MRI values are shown for individual thigh muscles. A composite value for all muscles combined is also shown. Significantly different or trending towards different from untreated control, same genotype; **indicates
statistical difference from untreated control, same genotype p < 0.01; ^indicates trending towards different from untreated control, same genotype p < 0.10.
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with NBD profoundly reduced myofiber size by 46%
(GRMD +NBD, n = 6, 1800 fibers) (P <0.05) compared
to untreated GRMD muscles.
We next determined whether NBD mitigated inflam-
mation. NBD treatment significantly reduced the num-
ber of PM2K-positive macrophages by 34% (P <0.05) in
the CS muscle compared to untreated GRMD dogs
(Figure 6A, Table 3). Necrosis and IgG-positive myofi-
bers were also reduced by 25% and 22%, respectively, in
NBD-treated dogs, but both of these indices only trended
toward significance (P = 0.14) (Figure 6B, 6C, Table 3).
Centrally located nuclei (CLN) were assessed to gauge re-
generation and were reduced by 43% (P <0.05) in NBDFigure 5 NBD treatment reduces damage-associated hypertrophy of
by H&E. (A) Representative sections at 20× magnification are shown from w
GRMD dogs treated with NBD. Scale bar = 50 μM. (B) Fiber diameter meas
treated with NBD (n = 2; 600 fibers), GRMD (n = 5; 1,500 fibers), and GRMDtreated versus untreated GRMD dogs (n = 5) (Figure 6D,
Table 3). This reduced regenerative response is consistent
with less pronounced necrosis and inflammation with
NBD treatment, but also implies that NF-κB inhibition
does not effectively enhance satellite cells to potently pro-
mote regeneration in dogs as previously observed in mice
[9,13,15,16]. Histopathological lesions were negligible in
NBD treated versus untreated wild type dogs (data not
shown). Analogous results with GRMD dogs were seen in
three other muscles (lateral head of the gastrocnemius,
vastus lateralis, and diaphragm). Composite scores for all
four muscles showed that NBD treatment reduced the
histopathological lesions of GRMD muscles by 35.5%
(Table 3; P <0.05, unless indicated). This protectiveCS muscles. Sections from the CS muscle were prepared and stained
ild type dogs, wild type dogs treated with NBD, GRMD dogs, and
urements were made from wild type (n = 2; 600 fibers), wild type
dogs treated with NBD (n = 6; 1,800 fibers).
Figure 6 NBD treatment improves the histopathological changes of GRMD cranial sartorius muscles. Muscle sections from the cranial
sartorius in GRMD and GRMD dogs treated with NBD were analyzed for different histopathology markers including (A) PM2K+ macrophages, as
an index of inflammation, (B, C) necrotic foci and IgG cytoplasmic localization, as markers of muscle injury, respectively, and (D) central nucleation, as a
marker of muscle regeneration. Asterisks indicate P < 0.05 (*).
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responses and MRI analysis discussed above. We have re-
ported similar favorable histopathological protection
against injury in the mdx model of DMD [9,13].
NBD treatment was not associated with biochemical or
hematologic changes
In addition to efficacy, we were interested in examining
the safety profile of NBD, since long-term dosing in any
animal model had yet to be performed. Blood samples at
pre-dose, mid dose, and terminal dose were obtained for
hematology and serum chemistry analysis. Results from
these evaluations showed no adverse effects in NBD
treated wild type or GRMD dogs (Additional file 2:
Figure S2 and Additional file 3: Figure S3).
Infusion reactions were seen in NBD-treated wild type
and GRMD dogs
After approximately 1 month of treatment, both wild type
and GRMD dogs developed infusion reactions of variable
severity in their response and duration. Many of these
signs were consistent with vasodilation/hypotension asso-
ciated with IgE-induced type 1 hypersensitivity reactions
in dogs, as seen with reactions to proteins in certainTable 3 Composite analysis of histopathology markers in NBD
Cranial sartorius Lateral gastroc
Inflammation 34 40
Necrosis (Foci,IgG) 25, 22 (p = 0.14) 34, 35
Regeneration 43 35
Histological markers of inflammation, necrosis, and regeneration were quantitatively as
gastrocnemius, vastus lateralis, and diaphragm). Percent differences between GRMD an
histological marker was determined for each muscle group. A final composite average
improvement from NBD treatment with regards to reducing inflammation, necrosis, anvaccines [50,51]. Blood pressure measured during admin-
istration of the compound was decreased in association
with some infusion reactions. NBD was initially dosed
over a period of 10 min. With the onset of reactions, the
perfusion time was extended to 30 min and dogs were
pretreated with diphenhydramine (Benadryl; 2 mg/kg SQ).
This seemed to partially reverse, but did not completely
eliminate the reactions. More severely affected dogs were
treated with intravenous fluids and diphenhydramine at
the onset of the reactions with some improvement.
Although the mechanism of these infusion reactions is
not clear, we felt they might be related to an immune re-
sponse. Therefore, serum from NBD treated dogs was
assayed by ELISA for anti-NBD IgG and IgE antibodies.
Levels of IgG, and to a lesser extent IgE, increased over
time with repeated IV administration of NBD during the
4-month treatment period (Figure 7A and 7B) in some
of the GRMD and wild type dogs. Necropsy analysis
demonstrated histopathological changes related to NBD,
seen principally in the spleen and lungs, and consistent
with antigenic stimulation and hypersensitivity [52,53].
In summary, our data support that NBD can be deliv-
ered to GRMD dogs over a 4-month period with improved
phenotypic outcome and no hematologic or blood-treated and untreated GRMD dogs
Vastus lateralis Diaphram Average rescue
31 37 35.5
35, 32 37, 32 35.3, 30.3
44 41 40.8
Final Histological Score of Improvement 35.5
sessed from sections prepared from 4 muscle groups (cranial sartorius, lateral
d GRMD+NBD treated dogs were calculated and an average value for each
from each of these values were also calculated to represent the overall percent of
d regeneration. For all values except where indicated, p < 0.05.
Figure 7 Levels of immunoglobulins are increased in NBD-treated dogs. Serum was collected as indicated in weeks during the 4 month
trial of NBD treatment on wild type (n = 2) and GRMD (n = 4) dogs. ELISAs were then performed to measure levels of (A) IgG and (B) IgE
compared to naïve canine serum used as a negative control. Values are shown for individual NBD-treated wild type and GRMD dogs. The black
bar serves as a negative control.
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nify a potential immune response to the peptide.
Discussion
As with other genetic diseases, treatment strategies for
DMD are proceeding on two tracks, one directed at
achieving a cure through genetic or cellular approaches,
and the other at reducing secondary effects of dys-
trophin deficiency such as inflammation and fibrosis
[54,55]. The use of glucocorticoids, which represents the
current standard of care for DMD, is an example of the
second treatment strategy. While prednisone and defla-
zacort delay the clinical progression of DMD, as docu-
mented by various outcome parameters [4,5], there are
numerous side effects [6]. Accordingly, complementary
and alternative forms of therapy, including compounds
that inhibit the classical NF-κB signaling pathway, are be-
ing sought [16,56-60]. To extend our prior work showing
benefit of NBD in the mdx and dko mouse models ofDMD [13,14], we were motivated to determine whether
NBD would have analogous benefits in GRMD dogs.
Results of our functional testing in NBD-treated GRMD
dogs showed a substantial increase in extension force and
a statistically insignificant paradoxical decrease in flexion
force. The increase in extension force is particularly mean-
ingful, since the current gold standard measure for DMD
clinical trials is to demonstrate functional benefit. Our
ability to collectively achieve such a benefit in GRMD
dogs, as well as in mdx diaphragm, [9,13] and dko hearts
[14], supports the pre-clinical efficacy of NBD. Due to in-
terspecies differences among mice, dogs, and humans, it is
difficult to say exactly how much functional improvement
in animal models would be needed to increase muscle
strength or quality of life in a DMD patient. However, the
significant functional responses previously seen in NBD-
treated rodent models (mdx diaphragm, 43% improve-
ment [13]; dko heart, improved back to wild type [14]),
and now in a canine model (GRMD, pelvic limb, 73%),
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tients. It is noteworthy that to date, no pharmacologic
agent has demonstrated the level of functional efficacy in
skeletal and cardiac muscles of mouse and dog DMD
models that we achieved with NBD.
Treated dogs also had improved histopathological in-
dices for inflammation and necrosis. We have previously
speculated that a trend towards reduced flexion force in
GRMD dogs treated with prednisone may reflect a re-
duction in necrosis that would otherwise lead to func-
tional flexor muscle hypertrophy [21]. A similar trend
towards reduced flexion force, as well as normalization
of other features of muscle hypertrophy such as CS myo-
fiber size and postural changes, were seen in NBD
treated GRMD dogs. Finally, beneficial functional and
histopathological features were reinforced by findings on
MRI. As expected, the level of eccentric contraction dec-
rement did not differ between NBD treated and control
GRMD dogs, reinforcing the fact that NBD’s therapeutic
benefit lies in its ability to reduce inflammation rather
than restore muscle membrane stability.
One histopathological feature that was not consistent
between NBD treated mdx mice versus GRMD dogs was
the regenerative response to muscle injury. In mdx mice,
NBD treatment caused a significant increase in muscle re-
generation (Figure 1 and [9,13]), in line with earlier find-
ings that NF-κB functions as a negative regulator of
skeletal myogenesis [61]. Selective genetic ablation of the
NF-κB signaling pathway in mdx muscles led to increases
in satellite cells, suggesting that constitutive activation of
NF-κB in dystrophic muscles functions to repress the re-
generative capacity of muscle stem cells [9]. Similar con-
clusions were reached in studies where NF-κB signaling
was ablated by stem cell replacement or gene therapy
[15,16]. It is unclear why NBD did not provide this same
benefit to GRMD dogs. One possibility, given the develop-
ment of IgG antibodies, is that NBD could have been neu-
tralized in the later portion of the study, masking a
potential enhanced regenerative response. Alternatively,
species differences could play a role. Mdx mice undergo
continual muscle regeneration throughout their lifespan.
In contrast, muscle regeneration in dystrophic dogs and
DMD patients diminishes over the progression of the dis-
ease, potentially due to their shorter telomere length [62]
and lower telomerase activity [63]. Thus, it is likely that
mdx satellite cells are more easily stimulated to expand
than canine or human cells. Perhaps, as discussed above
in the context of the reduced level of hypertrophy, the
relative reduction of necrosis in NBD treated dogs also
may have led to a less pronounced regenerative response.
As with any pre-clinical treatment trial in an animal
model, we were particularly interested in the safety profile
of our product. Notably, NBD treatment in the murine
models of DMD [9,13,14] and in numerous other mouseand rat models of disease associated with NF-κB signaling
had not reported any side effects. In our current 4-month
GRMD NBD trial, several dogs demonstrated infusion re-
actions characterized by features of vasodilation and
hypotension that appeared after about a month of treat-
ment. Although the mechanisms of action for these
responses are not clear, signs were indicative of hypersen-
sitivity reactions [50,51]. Some treated dogs also had IgE
and IgG antibodies reactive to NBD, lending further cre-
dence to a hypersensitivity reaction. Dogs have been used
to model hypersensitivity reactions in humans [64] and
there is considerable overlap in mast cell function between
the two species [65]. It is also possible that immunoglobu-
lins could have resulted from foreign sequences in NBD,
as the human version used for these studies differs from
that of dogs by two amino acids at the amino terminal end
[66]. Safety studies testing a dog version of NBD are cur-
rently underway. It is noteworthy that a distinct infusion
reaction was recently described in dogs with lymphoma
that received a single injection of NBD at 0.5 and 1 mg/Kg
[67]. A selective number of dogs developed moderate
hypertension soon after the administration of NBD that
resolved without treatment. Curiously, this reaction is op-
posite of the hypotension we observed in this study.
Because NBD-mediated responses seen in normal and
diseased dogs may be linked to an immune reaction, ef-
forts are underway to initiate formal pre-clinical toxicol-
ogy studies in non-human primates, whose immune
system more closely resembles man compared to dogs. In
a 28-day repeat dosing non-GLP study in non-human pri-
mates, systemic infusion responses reported here in dogs
were not observed (unpublished observations). However,
longer treatment trials with escalating drug doses will be
required to draw definitive conclusions on interspecies re-
actions to NBD treatment. Collectively, the phenotypic
benefits seen with NBD in our study are encouraging
given the small list of pharmacologic agents that have been
tested to date in larger DMD animal models.
Conclusions
In this study we show that administration of the small pep-
tide inhibitor NBD improves pelvic limb function and ame-
liorates skeletal muscle histopathological lesions in GRMD
dogs. These findings are consistent with earlier findings re-
ported in mdx mice, and together suggest that NBD pep-
tide therapy may be a realistic treatment option for DMD.
Additional files
Additional file 1: Figure S1. IV dosing of NBD exhibits a comparable
pharmacokinetic profile in mice and dogs. Plasma was prepared from
each blood sample collected at 0, 0.08, 0.25, 0.5, 1, 2, 4, 8, and 24 h
following IV dosing with NBD at 2 and 10 mg/Kg in normal mice (A,
n = 3/time point) and beagle dogs (B, n = 3/group).
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http://www.skeletalmusclejournal.com/content/4/1/18Additional file 2: Figure S2. Hematologic changes in NBD-treated
dogs. Serum was prepared from blood samples obtained at indicated
time points prior to and following dosing with NBD in wild type and
GRMD dogs. Serum samples were analyzed for complete blood counts
(CBC). The graphs show results for white blood cells, red blood cells, and
platelet counts.
Additional file 3: Figure S3. Clinicopathologic changes in NBD-treated
dogs. Serum was prepared from blood samples obtained at indicated
time points prior to and following dosing with NBD in wild type and
GRMD dogs. Serum samples were analyzed for ALT, AST, GGT, bilirubin,
creatinine, potassium, and creatine kinase.
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